Vendor Intelligence Report: Heman Peptide HM

Published 3 Jul 2026. 25-page investigative report on who is behind Heman Peptide HM: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 65 Finnrick lab tests, Heman Peptide HM posts 55 pass / 10 fail, an overall pass rate of 85%. The signal is product-specific, not brand-wide: GHK-Cu is the strongest relative choice, Retatrutide sits in the usable-but-batch-verified middle, and Tirzepatide is the caution product. Stricter grading makes the spread less forgiving.

The identity trail is less reassuring than the live storefront. WHOIS shows a renewed domain and continuing operation, while the public archive record remains thin. The corporate anchor in the source trail points to a Chinese sanitary-products profile listing diapers and pull-up diapers, not a verified peptide facility, and the site does not supply a named owner, quality officer, or authorized-agent roster.

Sales and accountability are routed through agents and semi-private channels: WhatsApp, WeChat, Discord, GLP1 Forum promotion, and Reddit referral traffic. The report maps those aliases separately rather than assuming one legal role. A named agent remains tied to an unresolved $3,000 non-fulfillment allegation, and community shipping records distinguish successful deliveries from slower US timelines and Canadian BAC-water seizures.

Buyer guidance is therefore narrow: Heman looks most defensible for GHK-Cu, requires fresh lot verification for Retatrutide, and is weakest for Tirzepatide. The full report shows the records behind that ranking before money changes hands.

Inside the full report:

  • Per-product pass/fail rates, spark-grid trajectories, and methodology-divergence charts for all three tracked products
  • Corporate identity map covering the Chinese B2B profile, address trail, and product-scope mismatch
  • WHOIS, Wayback, DNS, registrar, and June domain-renewal verification for hemanpeptide.com
  • Agent and channel map covering JolieHM, HM Boss, Discord, Mia Kuang, Ruby Lu, Iris, and Reddit referrals
  • Community fulfillment evidence: unresolved payment dispute, MT2 complaint, BAC-water seizure reports, shipping timelines, and payment rails
  • Affiliate/promotion scan and negative findings across GLP1 Forum, Reddit, X/coupon searches, TrustPilot, Janoshik, and certificate transparency

Risk assessment

  • Corporate-accountability opacity risk — high: Corporate anchor is Hebei Wangman Sanitary Products Co., Ltd., a Nov. 8, 2024 sanitary-products profile listing diapers/pull-up diapers; no peptide facility, named directors, physical storefront address, or corporate-domain email was verified.
  • Agent-mediated payment and fulfillment risk — high: Orders and support route through agents/WhatsApp/WeChat/Discord/private referrals; Reddit records include an unresolved $3,000 Mia Kuang non-fulfillment allegation.
  • Product-specific testing risk: Tirzepatide — medium: Finnrick lists Heman Tirzepatide at 75.33% (14 tests, 10 pass / 4 fail), materially weaker than GHK-Cu 91.28% and Retatrutide 86.06%.
  • Shipping/customs seizure risk for BAC-water orders — medium: Community reports cite Canadian seizures when bacteriostatic water was included and roughly three-week US timelines; avoid bundling BAC water if using Heman.
  • Affiliate/referral-promotion transparency risk — medium: GLP1 Forum sponsor promotion is disclosed, but Reddit DM-based WhatsApp referral promotion had no public disclosure and a field-material Instagram discount code had unclear disclosure; X/coupon sweeps found no broad public code network.